Pfizer Post-Earnings: Shorts Creep Back as Analysts Lift Targets

Pfizer has just reported Q3 results, and the market's immediate reaction is quietly telling: the stock slipped 2.2% on Tuesday to $30.00, paring a week that still closes up 0.7%, while short interest has nudged back upward after several weeks of retreat.

The short positioning shift is modest but worth noting. Short interest rose 5.3% across the week to 2.4% of the free float, reversing part of the sharp 11% monthly decline flagged in last week's earnings preview. At those levels the short thesis remains thin rather than aggressive. Borrow availability is effectively unlimited, with enormous headroom in the lending pool and a cost to borrow that fell 23% across the week to just 0.39%. Nothing in the lending market suggests conviction on the short side. The options market is similarly calm: the put/call ratio at 0.83 sits barely half a standard deviation above its 20-day average, well inside normal range and far from the 0.94 52-week high. Positioning, in short, looks mildly cautious rather than directionally charged.

The more interesting development this week is on the analyst side. RBC Capital raised its price target from $25 to $28 on Tuesday, maintaining a Sector Perform rating. That follows JP Morgan lifting its target from $28 to $30 in early October, also with no rating change. The pattern across recent weeks has been consistent: analysts are nudging targets higher but stopping short of upgrades. The consensus mean target now sits at $29.45, fractionally below the current price of $30.00, which puts the Street effectively at fair value. Bulls point to Pfizer's roughly $60 billion annual sales base, the durability of Ibrance and Eliquis, and international market exposure covering 40% of revenues. Bears flag rising gross-to-net adjustments on premium products and uncertainty around near-term revenue recognition. Factor scores add one genuinely bullish data point: the 12-month forward EPS year-on-year growth rank hits the 88th percentile, reflecting sharp recovery in forward estimates after post-Covid normalisation pressure. The earnings yield ranks in the 91st percentile, and the dividend score at the 93rd percentile reflects the stock's yield appeal at current prices.

Retail attention spiked notably around the earnings date. Wikipedia page views carried a z-score of 2.16 against the prior 90-day average as of late October, well above normal. None of Pfizer's alt data datasets carry a measured lead against the company's reported figures, so that attention reading is colour rather than a signal about the print itself. What the Medicaid data does show, as a factual matter, is that Medicaid units reimbursed were down 17% year-on-year in Q1 2026, and Medicaid prescriptions fell 21% over the same period, a drag the bears have already built into their gross-to-net adjustment concerns.

The insider story, the standout from the pre-earnings note, has not changed in substance. CEO Albert Bourla's $1 million open-market purchase in August at $26.34, alongside near-identical buys from directors Blaylock and Buckley at similar prices, still represents close to $3 million in discretionary buying at levels roughly 14% below where the stock trades today. Net insider buying across the 90-day window totals around 111,000 shares worth $2.9 million. That signal was placed before the Q3 print; it now sits as context for how management read the setup heading in.

Among peers, BMY fell 2.1% on the day, broadly matching Pfizer's move. LLY was flat, and MRK dropped 2.5%. The parallel softness across large-cap pharma on Tuesday suggests sector rotation rather than a Pfizer-specific reaction. The next scheduled print is 2 February 2027. Between now and then, the question the data sets up is whether the modest short interest rebuild reflects genuine post-earnings disappointment or simply mean reversion after several weeks of heavy short covering.